Lantheus (NASDAQ:LNTH) Reaches New 1-Year High – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH) reached a new 52-week high on Friday . The stock traded as high as $103.89 and last traded at $103.00, with a volume of 2009265 shares trading hands. The stock had previously closed at $94.47.

Analyst Upgrades and Downgrades

LNTH has been the subject of several analyst reports. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Truist Financial reissued a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Citizens Jmp boosted their price target on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Finally, Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.71.

Lantheus Stock Up 9.0%

The company has a fifty day simple moving average of $83.62 and a 200-day simple moving average of $71.76. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm has a market cap of $6.71 billion, a P/E ratio of 24.82 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the company posted $1.53 earnings per share. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently bought and sold shares of the business. Western Wealth Management LLC purchased a new stake in Lantheus in the 1st quarter worth $25,000. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the 2nd quarter worth $36,000. Hantz Financial Services Inc. increased its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Finally, Bessemer Group Inc. increased its stake in Lantheus by 221.3% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.